Lucid Diagnostics (LUCD) reported a strong fourth quarter, with EsoGuard test volumes reaching 3,664—well above the target range of 2,500 to 3,000—marking a 29% increase. Revenue also rose by 24% to $1.5 million, driven by the company’s strategic focus on expanding access to Medicare and the Veterans Affairs (VA) market. The recent award of a VA Federal Supply Schedule contract aligns pricing with Medicare rates, potentially opening up testing for 9 million veterans.
The implications for Lucid are significant, as management anticipates a substantial portion of the veteran population will be recommended for testing. Additionally, the company is nearing a critical milestone with the expected publication of a draft Local Coverage Determination (LCD) for Medicare, which could lead to retroactive payments for claims dating back a year. This positions Lucid for potential revenue growth as it continues to enhance its commercial payer relationships.
For market professionals, Lucid’s advancements in test volume and payer engagement signal a pivotal moment that could enhance revenue streams and operational leverage, particularly as Medicare coverage becomes more certain.
Source: fool.com